Market Intelligence & Cybersecurity for MedTech

Part of our Medical device cybersecurity strategy, culture, and lifecycle series. For the full overview, start with Total Product Lifecycle Security for Devices.

Why this matters

The FDA’s final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (Feb 3, 2026), sets out cybersecurity documentation expectations for premarket submissions. For devices subject to Section 524B of the FD&C Act, cybersecurity information is a submission requirement, not an optional supporting attachment. Teams must account for those expectations alongside software lifecycle processes under IEC 62304 and security risk management under AAMI TIR57 and ANSI/AAMI SW96:2023.

Documentation gaps are a common source of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2025 MDUFA Performance Report lists cybersecurity among the subject-matter expert areas that may be involved in reviewing a device submission, alongside sterility, biocompatibility, and software. The practical problem is often not a missing document. It is a document that makes a claim without enough detail to evaluate it.

In the FDA letters we reviewed for our September 2026 MTEC webinar, one letter raised the same issue nine times against nine different security controls: the submission described a principle rather than an implementation. Examples of this pattern included naming TLS 1.2 without cipher suites or ECDSA without the curve and hash function. Our formal analysis covered ten letters, not all submissions industry-wide.

For a MedTech leader, that distinction matters. “We have cybersecurity documentation” is not the same as “our requirements, implementation, and test evidence agree.”

The Intersection of Data, AI, and Cyber in the MedTech Industry

Market intelligence and cybersecurity answer different questions. Market intelligence asks who needs the product, what has changed in their business, and when to approach them. Cybersecurity asks what an attacker can reach, what harm could follow, and whether the controls work.

We connect the two at the point where commercial claims need engineering evidence. A sales team may identify a promising health-system buyer. The manufacturer still needs to explain device interfaces, update support, secure configuration, and vulnerability handling. Finding the opportunity is only part of the work.

AI can help process market signals. It does not remove the need to check their meaning, just as an automated vulnerability scan does not establish the patient-safety impact of a finding.

Bridging the Regulatory Gap: MedTech’s 5-Year Lag Behind Pharma

Kevin Saem, founder of Zapyrus, a SaaS platform for MedTech sales and marketing, estimates that MedTech trails pharma by about five years in regulatory sophistication, sales processes, and company maturity.

“The MedTech space has been historically 5 years minimum behind life sciences like pharma and biotech, from a regulatory standpoint,” Saem says. “This then bleeds down into the innovations, tools, and sales team structure and sophistication used in the space.”

We would treat that as Saem’s industry assessment, not a measured lag that applies to every manufacturer. Its useful lesson is narrower: teams cannot assume that established processes will arrive before they need them.

A less mature process may leave room to move quickly. It can also leave unclear ownership for security decisions and compliance evidence. The allegations discussed in the Illumina incident show why the integrity of that evidence deserves management attention, not just a final document review.

Harnessing the Power of Market Intelligence and AI

Saem founded Zapyrus to give MedTech service providers a central source of market intelligence and sales-enablement data. The aim is to reduce the time salespeople spend finding, processing, and qualifying information before they can use it.

“They don’t want to spend time, hours and hours and hours processing data, turning through data, qualifying data. They want to sell and grow their business,” Saem explains.

Zapyrus uses machine learning and AI to identify market signals and triggers. Its CRM integrations put that information into the sales workflow, helping teams approach potential customers when there is a reason to engage.

We see a useful discipline here: a signal should lead to a decision. Collecting more market data is not progress if nobody changes an account priority or outreach plan. The same applies to security. A finding needs an owner, a risk decision, and evidence of the resulting action.

The Shifting Tides of MedTech Investment

The European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) changed the requirements manufacturers must plan around. Saem described an investment pattern that ran against the expectation that tighter regulation would simply drive capital away.

“What our data showed was actually the opposite in this past quarter Q2 - Europe surpassed North America in terms of rate of growth in financial investment in MedTech,” Saem says. He attributed that shift to greater regulatory stability: investors knew the rules they were funding companies to meet.

That observation concerns the quarter and dataset he described, not a permanent regional advantage. The business lesson still holds: uncertainty makes planning harder.

We apply that lesson to cybersecurity diligence. A manufacturer that can explain its remaining security work, patch path, and residual risks gives investors something concrete to assess. “We will address security before submission” leaves the cost and schedule unresolved.

The Growing Importance of Cybersecurity in MedTech

Connected devices expose more than patient data. Wireless configuration, firmware updates, companion apps, and cloud services can affect how a device operates. AI and machine learning add further questions about data integrity and system behavior.

On a Class II wearable we tested, the BLE firmware-update bootloader checked a CRC but not a cryptographic signature. We modified one byte in a captured firmware image and replayed it. The device installed the modified image and rebooted into it. A successful transfer check had been mistaken for proof of firmware authenticity.

The recommended controls were specific: ECDSA P-256 image signing, signature verification in the bootloader before commit, a write-protected public key, and a monotonic version counter to prevent rollback. This is the difference between saying “updates are protected” and specifying what protection means.

The allegations that Illumina falsified cybersecurity compliance evidence raise a separate issue: whether the evidence can be trusted. The reported AI therapy failure, in which an AI system instructed a suicidal patient to end their life, concerns unsafe system behavior. We should not present that event as proof of a cyberattack. Both cases demand patient-safety attention, but their causes and controls must be assessed separately.

Proactive Cybersecurity: A Necessity for MedTech Innovation

See also: What Is MedTech? MedTech vs Medical Device vs Life Sciences, 8 FDA Cybersecurity Deficiencies, Ranked From Real Letters, and CVSS Scoring for Medical Devices: A Complete Walkthrough.

Late security work creates three business exposures:

• Regulatory delays: Unaddressed cybersecurity issues can cause 12-month delays in FDA clearance. That is a possible consequence, not a standard review duration or a prediction for every submission. For a startup, the effect on runway can be severe.
• Investor concerns: Cybersecurity plans affect how investors assess regulatory risk, valuation, and reputation. An unfunded remediation backlog is a business liability.
• Patient safety risks: Vulnerabilities can affect device operation, while unsafe AI behavior can create harm without an attacker. Neither belongs outside the product’s risk process.

Saem argues that manufacturers need to act before regulation catches up with every new technology.

“You need to take the ownership and put the patient first and take the proactive steps to ensure that you have proper measures in place,” he says. “You almost need to self-regulate to some extent so that you allow time for a slow-moving organization like the FDA to kind of catch up, because it’s changing so quickly.”

We agree with taking ownership, with one qualification: self-regulation supplements existing obligations. It does not replace them. The practical work is to identify attack paths, define controls, test them, and plan how fielded devices will receive fixes.

Timing is Everything: When to Invest in Sales Enablement and Cybersecurity

The investment triggers are different.

Saem places the sales-enablement trigger at the point where a company wants to grow beyond word-of-mouth and repeat business. That is when a CRM, contact tool, database, or market-intelligence platform can support a repeatable sales operation.

Cybersecurity cannot wait for that commercial milestone. It needs to influence architecture while the team can still change authentication, interfaces, and update mechanisms without rebuilding the product.

In our September 17, 2026 secure-by-design workshop in Singapore, we used an illustrative wireless-device example to show that sequence. The threat was spoofing through unauthenticated pairing. The control was per-device certificate authentication. The proposed penetration test checked whether the device rejected unauthenticated pairing. This was a teaching example, not a reported client outcome, and its point was traceability from threat to control to test.

This is the part teams skip: budgeting for the decisions and engineering changes that the evidence may require. Buying a test near submission does not buy back the opportunity to design a better update path months earlier.

Conclusion

Market intelligence helps a MedTech company find and qualify demand. Cybersecurity helps it deliver a product whose security claims can withstand scrutiny. Neither substitutes for the other.

We recommend planning both as operating work: maintain the sales data, assign owners to security risks, and fund the controls and testing before deadlines force shortcuts. Regulatory clarity helps, but execution still depends on the manufacturer.

To learn more about how Zapyrus can help your MedTech business streamline its sales and marketing, visit their website. To explore how Blue Goat Cyber can help secure your medical devices and protect patient safety, schedule a Discovery Session.

How Blue Goat approaches this

We focus exclusively on medical device cybersecurity, including threat modeling, security risk management, SBOM work, architecture views, penetration testing, and regulatory submission support. We treat documentation as evidence of engineering decisions, not a substitute for them.

Our approach connects threats, control requirements, security test results, and residual-risk decisions. For penetration-test findings, we document reproduction steps and impact, with traceability to the device’s ISO 14971 risk file. We provide security testing, not the manufacturer’s software verification and validation.

We scope the work against the device’s interfaces, risk profile, and existing evidence, including its IEC 62304 lifecycle context and applicable expectations in the Feb 3, 2026 guidance. We also help manufacturers assess FDA cybersecurity deficiency letters and identify the evidence needed to respond. See our medical device cybersecurity services for the available scope.

If you want one team to own the whole cybersecurity package, see our full-service FDA premarket cybersecurity support.

Related reading: Cybersecurity as a MedTech Differentiator: A 2026 Playbook for MedTech Leaders, Cybersecurity Neglect in MedTech: A 2026 Playbook for MedTech Leaders.

FAQ

How does market intelligence benefit MedTech companies?

Market intelligence tools identify signals that help sales and marketing teams prioritize accounts and time their outreach. CRM integration makes those signals available where the sales team works. The benefit depends on using the data to make decisions, not simply collecting it.

Why is cybersecurity important for MedTech investment?

Cybersecurity affects regulatory risk, remediation costs, reputation, and patient safety. Investors can assess those exposures more clearly when a manufacturer has documented risks, tested controls, and a funded plan for updates and vulnerability response.

What regulatory challenges does the MedTech industry face?

Saem estimates that MedTech trails pharma by about five years in regulatory and operational maturity. Manufacturers also face changing requirements across markets. EU MDR and IVDR provide clearer rules to plan against, but meeting those rules still requires evidence and resources.

Does proactive cybersecurity affect FDA clearance timelines?

Yes. Unaddressed cybersecurity issues can contribute to clearance delays of 12 months or more, although there is no universal delay length. Early threat modeling, specific control requirements, and security testing help reduce avoidable rework. They do not guarantee clearance or a particular review timeline.

When should MedTech companies invest in cybersecurity and sales enablement?

Start cybersecurity during design and maintain it through the device lifecycle. Invest in sales-enablement tools when the business needs to grow beyond referrals and repeat customers. Security work should not wait until the sales operation is ready to scale.

How does MedTech self-regulation relate to FDA guidance?

Manufacturers may need to address emerging risks before the FDA publishes technology-specific guidance. That means applying established security practices to new attack paths and unsafe behaviors. It supplements, rather than replaces, compliance with current requirements.